Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.46 |
| ▸ | PDE4A | P27815 | 8/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13165899 | 0.92 | PDE4A (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5513420 | 0.92 | PDE4A (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1825058 | 0.89 | PDE4B (0.43) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL13165893 | 0.88 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5515932 | 0.88 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5509182 | 0.87 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1826949 | 0.87 | PDE4B (0.48) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6843737 | 0.87 | PDE4B (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5511996 | 0.87 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL13002994 | 0.87 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076369-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-12-13 | — | — | US | claimed |
| US-7662847-B2 | Myelodysplastic syndrome, Parkinson*s disease, multiple sclerosis, AIDS, chronic obstructive pulmonary disease, acquired respiratory distress; analgesics, angiogenesis inhibitors; anticarcinogenic and antitumor agents; phopshodiesterase, tumor necrosis factor and matrix metalloproteinase inhibitors | CELGENE CORPORATION (US) | 2010-02-16 | — | — | US | claimed |
| US-6911464-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2005-06-28 | — | — | US | claimed |
| US-20040259873-A1 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | AMGEN INC. | 2004-12-23 | — | — | US | claimed |
| US-8076369-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1606256-B1 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | CELGENE CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7662847-B2 | Myelodysplastic syndrome, Parkinson*s disease, multiple sclerosis, AIDS, chronic obstructive pulmonary disease, acquired respiratory distress; analgesics, angiogenesis inhibitors; anticarcinogenic and antitumor agents; phopshodiesterase, tumor necrosis factor and matrix metalloproteinase inhibitors | CELGENE CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1606256-A2 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050203090-A1 | Methods of using N-alkyl-hydroxamic acid-isoindolyl compounds | AMGEN INC. | 2005-09-15 | — | — | US | disclosed |
| US-6911464-B2 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040259873-A1 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | AMGEN INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080422-A2 | N-ALKYL-HYDROXAMIC ACID-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259873-A1 | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4C 5/4885PDE4A 1/4885 |
| US-20050203090-A1 | Methods of using N-alkyl-hydroxamic acid-isoindolyl compounds | PDE4A, PDE4B, PDE7A | PDE4B 2/4885PDE4C 5/4885PDE4A 1/4885 |
| US-20100267800-A1 | N-Alkyl-Hydroxamic Acid-Isoindolyl Compounds and Their Pharmaceutical Uses | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4C 5/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.